Literature DB >> 25761313

Complement-mediated haemolysis and the role of blood transfusion in paroxysmal nocturnal haemoglobinuria.

Tolulase Olutogun1,2, Ilaria Cutini3, Rosario Notaro1, Lucio Luzzatto4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25761313      PMCID： PMC4614287          DOI： 10.2450/2015.0249-14

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  55 in total

1.  Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME).

Authors:  Elliott Vichinsky; Lynne Neumayr; Sean Trimble; Patricia J Giardina; Alan R Cohen; Thomas Coates; Jeanne Boudreaux; Ellis J Neufeld; Kristy Kenney; Althea Grant; Alexis A Thompson
Journal:  Transfusion       Date:  2013-07-25       Impact factor: 3.157

Review 2.  Diagnosis and management of paroxysmal nocturnal hemoglobinuria.

Authors:  Charles Parker; Mitsuhiro Omine; Stephen Richards; Jun-Ichi Nishimura; Monica Bessler; Russell Ware; Peter Hillmen; Lucio Luzzatto; Neal Young; Taroh Kinoshita; Wendell Rosse; Gerard Socié
Journal:  Blood       Date:  2005-07-28       Impact factor: 22.113

3.  Targeted therapy with eculizumab for inherited CD59 deficiency.

Authors:  Britta Höchsmann; Christian Dohna-Schwake; Henriette A Kyrieleis; Ulrich Pannicke; Hubert Schrezenmeier
Journal:  N Engl J Med       Date:  2014-01-02       Impact factor: 91.245

Review 4.  Red blood cell alloimmunization in sickle cell disease and in thalassaemia: current status, future perspectives and potential role of molecular typing.

Authors:  A Matteocci; L Pierelli
Journal:  Vox Sang       Date:  2013-10-09       Impact factor: 2.144

Review 5.  Review: Cromer and DAF: role in health and disease.

Authors:  D M Lublin
Journal:  Immunohematology       Date:  2005

6.  CD59 deficiency is associated with chronic hemolysis and childhood relapsing immune-mediated polyneuropathy.

Authors:  Yoram Nevo; Bruria Ben-Zeev; Adi Tabib; Rachel Straussberg; Yair Anikster; Zamir Shorer; Aviva Fattal-Valevski; Asaf Ta-Shma; Sharon Aharoni; Malcolm Rabie; Shamir Zenvirt; Hanoch Goldshmidt; Yakov Fellig; Avraham Shaag; Dror Mevorach; Orly Elpeleg
Journal:  Blood       Date:  2012-11-13       Impact factor: 22.113

7.  Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria.

Authors:  Anita Hill; Peter Hillmen; Stephen J Richards; Dupe Elebute; Judith C Marsh; Jason Chan; Christopher F Mojcik; Russell P Rother
Journal:  Blood       Date:  2005-06-28       Impact factor: 22.113

8.  Genetic variants in C5 and poor response to eculizumab.

Authors:  Jun-ichi Nishimura; Masaki Yamamoto; Shin Hayashi; Kazuma Ohyashiki; Kiyoshi Ando; Andres L Brodsky; Hideyoshi Noji; Kunio Kitamura; Tetsuya Eto; Toru Takahashi; Masayoshi Masuko; Takuro Matsumoto; Yuji Wano; Tsutomu Shichishima; Hirohiko Shibayama; Masakazu Hase; Lan Li; Krista Johnson; Alberto Lazarowski; Paul Tamburini; Johji Inazawa; Taroh Kinoshita; Yuzuru Kanakura
Journal:  N Engl J Med       Date:  2014-02-13       Impact factor: 91.245

Review 9.  Complement and its receptors: new insights into human disease.

Authors:  V Michael Holers
Journal:  Annu Rev Immunol       Date:  2014-01-29       Impact factor: 28.527

10.  Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.

Authors:  Antonio M Risitano; Daniel Ricklin; Yijun Huang; Edimara S Reis; Hui Chen; Patrizia Ricci; Zhuoer Lin; Caterina Pascariello; Maddalena Raia; Michela Sica; Luigi Del Vecchio; Fabrizio Pane; Florea Lupu; Rosario Notaro; Ranillo R G Resuello; Robert A DeAngelis; John D Lambris
Journal:  Blood       Date:  2014-02-04       Impact factor: 22.113
View more
  3 in total

1.  Childhood aplastic anaemia with paroxysmal nocturnal haemoglobinuria clones: A retrospective single-centre study in South Africa.

Authors:  Candice L Hendricks; Ashen Naidoo; Rajendra Thejpal; Nadine Rapiti; Beverley Neethling; Yasmin Goga; Suvarna Buldeo
Journal:  Afr J Lab Med       Date:  2022-06-06

2.  Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.

Authors:  Michela Sica; Tommaso Rondelli; Patrizia Ricci; Maria De Angioletti; Antonio M Risitano; Rosario Notaro
Journal:  J Hematol Oncol       Date:  2017-06-19       Impact factor: 17.388

3.  Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population.

Authors:  Wendy Y Cheng; Sujata P Sarda; Nikita Mody-Patel; Sangeeta Krishnan; Mihran Yenikomshian; Malena Mahendran; Dominique Lejeune; Louise H Yu; Mei Sheng Duh
Journal:  Adv Ther       Date:  2021-07-17       Impact factor: 3.845
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.